AVAC is delighted to announce the 2020 AVAC Advocacy Fellows, ushering in the new decade as the 11th class of the Fellows Program! As we mark this milestone of the program in 2020, we will be reflecting on the lessons and accomplishments of the last decade and looking forward to how the Fellows program can continue to help strengthen the HIV prevention movement.

Seven 2020 Advocacy Fellows have been selected from a pool of more than 150 applicants from 24 countries. We are happy to welcome our new class and our first Fellow from Eswatini. We thank all of the applicants and their proposed host organizations for the time and effort put into the application process. We’re also grateful to the independent review committee of advocates, scientists and former Fellows and hosts who guided our decision-making.

Join us in welcoming the seven 2020 AVAC Advocacy Fellows and their host organizations:

• Josephine Aseme, Heartland Alliance, Nigeria
• Chisomo Chaweza, Malawi Network of Religious Leaders Living With HIV, Malawi
• Lomcebo Dlamini, Super Buddies Club, Eswatini
• Mandisa Dukashe, Wits Reproductive Health and HIV Institute, South Africa
• Winifred Ikilai, National Forum of People Living with HIV & AIDS Networks in Uganda, Uganda
• Joyce Ouma, National Empowerment Network of People Living With HIV/AIDS in Kenya, Kenya
• Esnart Sikazindu, Community Based TB/HIV/AIDS Organisation, Zambia

The 2020 Fellows’ year begins in April at a time when there are critical issues demanding action in the HIV prevention field to advance our collective goal of ending the epidemic. Among these issues are the anticipated regulatory opinion on the dapivirine ring; trial results from the AMP study; possible preliminary results from long-acting injectable PrEP; implications of the early stop of continued vaccinations in the HVTN 702 vaccine trial; the development of a novel trial design to study oral F/TAF as PrEP in women; advances toward a possible dual pill for HIV prevention and contraception; new global targets for prevention; evaluation of innovative prevention delivery under PEPFAR’s DREAMS program; and understanding the recent “universal test and treat” trial results.

Please visit the Advocacy Fellows page to learn more about their planned work for the year. We hope you’ll find ways to collaborate with them in 2020 and beyond.

The 2020 Fellows join a group of 70 current Advocacy Fellows and alumni from ten countries who have participated in the program over the last 10 years.

A Call for Applications for the 2021 Fellows Program will be announced mid-2020. If you would like to be notified or have any questions, please email us at fellows@avac.org.

And stay tuned for more information about the 10 years of the Advocacy Fellows Program!

AVAC’s Anabel Gomez and Shawn Malone have contributed a chapter, “Understanding HIV prevention in high-risk adolescent girls and young women in two South African provinces”, in the 22nd edition of the South African Health Review (SAHR).

These findings are part of a research project Breaking the Cycle of Transmission, conducted under AVAC and CHAI’s HIV Prevention Market Manager (PMM). Funded by the Bill & Melinda Gates Foundation, PMM is applying behavioral research and human-centered design to better understand and reach young women in South Africa with effective HIV prevention.

Read the full article.

For more information:

• This webinar on the quantitative phase of the research explores the findings from a survey of almost 2,000 adolescent girls and young women on the factors that influence their decisions and behaviors along a sexual and reproductive health journey.
• This webinar presented qualitative findings with a discussion on the implications of emerging insights.
• The PrEP Virtual Learning Network provides tools, resources and opportunities to learn from other efforts scaling-up PrEP.

This update contains background information and an action alert on index testing. While this approach to HIV testing (see below for a definition) has potential benefits for individuals and communities when it is done ethically, with consent and without coercion, it can also be aggressively implemented in ways that can cause harm to individuals, undermine their rights to consent, privacy, safety and confidentiality, and can erode the trust of communities with health care providers.

Download an FAQ with background and opportunities for advocates to engage.

This is a rapidly evolving area of discussion with the PEPFAR Office of the Global AIDS Coordinator (OGAC), country teams, CDC, USAID and other partners. For activists and advocates attending PEPFAR in-country retreats—here are some top-line concerns and demands to consider, discuss and push for:

• All index testing programs should be immediately paused while risk mitigation and mediation efforts are put in place. Civil society rejects any PEPFAR guidance that only key populations (KP) programs need to deal with this issue or that index testing is only halted for members of KPs. Many key populations test in general population health facilities where disclosing their partners may risk discrimination and violence. Cisgender women and adolescent girls and young women (AGYW) face equally high risk of adverse events related to index testing. Their needs will not be met by KP-specific interventions.
• Targets that set a percent of HIV-positive individuals that must be identified via index testing cannot be part of Country Operational Plans (COPs) for 2020. These targets apply pressure to programs and implementing partners, and send the message that the target matters more than the quality of service and the rights of patients. Moreover, such targets can’t be set while index testing is paused and remediation is underway.
• Civil society must be involved in the development of the certification processes for restarting index testing and in the implementation of monitoring. Civil society partnership in providing support and monitoring is needed on an ongoing basis and should be a part of COP2020 budgeting for index testing programs.

Please reach out with questions, contact us if you have reports of harm, and join us in action.

A new episode of our Px Pulse podcast is ready for download!

2020 Global Targets for Prevention Will Not Be Met: Now What? In this episode, hear about AVAC’s answers to this question in our analysis of the state of the field laid out in AVAC’s annual report.

With unmet UNAIDS “Fast-Track” targets for ending the epidemic now a reality, the field faces the sobering truth that we’ve been striving towards the 90-90-90 treatment targets without the same enthusiasm, focus and commitment to primary prevention targets.

AVAC’s Emily Bass and lead author of our repot Now What? joins this episode of Px Pulse to talk about AVAC’s blueprint for course correcting—bold leadership, smart target-setting for HIV prevention research and implementation, and multilayered prevention programs that are centered around people. She explains why the epidemic needs a sustained response and how leaders from the highest level down to the grassroots can demand accountability and reject a “business as usual” approach.

For the full podcast episode, highlights and resources, visit avac.org/px-pulse. And subscribe on Apple Podcasts, Spotify or wherever you get your podcasts!

Matthew is the Director of US Policy & Advocacy at HealthGAP. He is also community co-chair of the Microbicide Trials Network, member of the Vaccine Advocacy Resource Group (VARG), Board of Directors member for the AIDS Treatment Activist Coalition (ATAC) and a member of AVAC’s PxROAR United States program.

For 30 years, everyone fighting to defeat HIV put hope in being the last generation impacted by HIV. This hope kept those of us from key populations fighting, kept us moving and kept us working to save ourselves and our communities. We believed that with bold action and resolve we could make real something that has only been seen through the lens of mathematical models and hypothetical propositions. And yet progress is slipping away through our fingers. Our colleagues and brothers and sisters, in solidarity, have achieved much in eastern and southern Africa, seeing millions receive treatment and the benefits of viral suppression. Yet in so many contexts, a lack of will has stalled progress that is essential if our hopes are ever to come true. A lack of urgency, resources, and the political will to bring our most powerful interventions to bear has brought the field to a fork in the road. We have arrived at a moment that shows us what is possible, or we could backslide away from the gains so hard won in recent years.

In 2014, UNAIDS and partners launched a “Fast Track” strategy to end AIDS by 2030. It was called a leap forward, laying out a plan to quicken the implementation of proven treatment and prevention interventions with milestones or targets to be met by 2020, setting the world on a trajectory to end the AIDS epidemic by 2030. In 2014 this was to be the blueprint for the work ahead.

Many of these targets will be missed in 2020, that is known. But understanding why we didn’t make it and what must change will be the true testament of our moment. The field can deploy our newfound knowledge of the last six years, collaborate with communities, and fill in the gaps so that we develop programming that is adaptive and meaningful in the lives of the communities that must be reached. With smarter, more adaptive plans, fed by what we’ve learned, we’ll set in motion proactive, grounded strategies that, at their core, are centered around those most affected.

The past six years have brought important new lessons and reinforced ones we’ve known a long time. We understand the power of treatment and the challenge of sustaining people’s connection to care. We’ve seen again the importance of programs that take aim at the structural drivers of the epidemic for the most at-risk groups. The prevention package expanded, and as it continues to grow so does our understanding our how to best work with communities. The field is exploring and refining how to build solid programs that are rooted in science and adapted to fit the needs of particular people, places, and priorities. All this will come into full strength if we follow a path carved by deep community engagement because we know community has the power to change the world.

So when I asked the question “Now what?” I say we continue to cycle out programs that aren’t working or are no longer relevant to people’s experiences, making new models that speak to the needs of the community. And that we do it with the single-minded purpose of ending the pandemic while maintaining justice and bending it towards equity. We must explain how this work fits into people’s lives. We must be a groundswell. We are in a transformative time. A sprint towards strong targets over the next 10 years, one that is bold daring and inclusive, even if we come up short will save millions of lives. We have to be able to explain the why and how of what has changed already, what must still be done, and how it all makes people’s lives better than the day before, and better for the day to come…if we pull together.

So that is what we do now.

Prince is a proud and out trans man and human rights activist in Malawi. He is affiliated with LITE (Lesbian Intersex Transgender and other Extensions). Prince advocates for the eradication of stigma and discrimination faced by the LGBTIQ community accessing public services, affecting health, security, justice and economic opportunities. He teaches a class on gender, sexuality, and the acceptance of LGBTI persons at Lilongwe University of Agriculture and Natural Resources, and is a member of AVAC’s PxROAR Transgender program.

Many LGBTIQ activists are failing to understand the intersectionality of the fight against HIV/AIDS, decriminalization of same-sex marriages and the struggle towards freedom. In October 2019, I had an opportunity to attend the 4th Biannual Trans Conference in South Africa. Here I heard activists decry the link between HIV/AIDS and escalating violence against LGBTIQ persons, a doubling of stigma. As a human rights defender and an activist for biomedical HIV prevention methods, I was dismayed to learn how activists attempt to distance themselves from HIV programming to focus exclusively on human rights issues. But as I sat listening to the discourse and reflecting on my country, Malawi, I couldn’t fault their arguments, derived from concerns about persistent and widespread stigma against LGBTIQ communities.

I have realized that when it comes to HIV programming for key populations, what many stakeholders think of when they hear about LGBTIQ persons are lubricants, condoms and PrEP. If this kind of inventory is unavailable or hard to get for key populations, you can hear voices chime up, demanding access to these life-saving resources. But many of these same voices grow quiet at other times, unwilling to openly denounce inhumanity that happens to LGBTIQ persons.

In Malawi, a lot of violence and brutality is pointed at LGBTIQ persons, but a strong cross-section of allies consistently coming forward to condemn such inhumane acts is missing. They choose to play the background role and face each day as if nothing happened. But who will blame them, when considering the heteronormative and religious bigotry which continues to marginalize LGBTIQ persons all over the world. I remember attending a forum where one member loudly said that training 100,000 healthcare workers on sexual orientation, gender identity and gender expression (SOGIE) would not be enough to overcome the barriers that block access to healthcare for LGBTIQ persons. She went on to say that it’s not a question of knowledge, but one of perception. In her concluding remarks she said, and I quote, “even some of us here, we accept you only in this space but when we are home we sit and say ‘mmmh.’”

I really applaud UNAIDS efforts to fight for equality for LGBTIQ persons, and they do more than merely react when attacks are made against LGBTIQ activists. UNAIDS sets the pace for key population HIV programming in so many countries, including Malawi. Much as I am tempted to call for stakeholders and allies to imitate UNAIDS in the fight for justice for LGBTIQ persons, I also want people to have honest conversations with themselves first. People need to evaluate and analyze their own personal prejudice and values against LGBTIQ persons, and, I hope, come to the realization they can fully commit themselves to the fight for justice. We need allies that are bold, courageous, fearless and honest to stand with us in the fight for justice within programming for HIV key populations and beyond it.

Launched on World AIDS Day in December, AVAC has another installment of our blog carnival Generation Now Responds. In AVAC Report 2019: Now What?, we called out to young advocates, members of “Generation Now”, encouraging them to sustain their bold efforts in the fight against HIV. In Part II of the series, Matthew Rose answers with a sweeping view of the history of the epidemic and what must come next and Prince Mikel Juao gives readers a view on what the fight looks like in Malawi, where stigma can be an overwhelming force.

• Matthew Rose, United States
• Prince Mikel Juao, Malawi

Eliminating TB by 2030—the timeframe set by United Nations member states—will not be possible without developing and introducing new TB vaccines. Decades of investments in TB vaccine research and development are starting to pay off — join fellow advocates to learn about the latest in TB vaccine research and discuss next steps based on recent results!

Join Treatment Action Group (TAG) and AVAC on Thursday, February 6, at 9am New York | 3pm Geneva | 4pm Cape Town | 7:30pm Delhi for a webinar featuring an update on recent vaccine results and possible next steps with M72/AS01E, one of several new TB vaccine candidates.

REGISTER HERE.

The TB vaccine field is buzzing in 2020, with at least two Phase II trials reporting positive results in the past two years and several other trials either underway or close to finishing. Of particular interest, the positive finding in a Phase IIb trial of TB vaccine candidate M72/AS01E provided 50 percent protection against developing TB disease in HIV-negative adults with TB infection. The Phase IIb trial of this candidate vaccine was sponsored by GlaxoSmithKline (which developed it) and funded by GSK and Aeras (now IAVI).

Next month’s webinar will feature Dereck Tait from IAVI who will present an overview of the M72/AS01E Phase IIb trial results, and Johan Vekemans from the World Health Organization (WHO) who will summarize a series of WHO-hosted consultations on the path forward for M72/AS01E’s development and possible licensure.

Presentations by:

• Johan Vekemans | World Health Organization, Initiative for Vaccine Research, Geneva, Switzerland
• Dereck Tait | IAVI, TB Program, Cape Town, South Africa

Q&A and discussion moderated by:

• Mike Frick | TAG, TB Project co-director
• Stacey Hannah | AVAC, Director of Research Engagement

If you’re looking for background information in advance of the webinar, here are some useful resources:

• WHO’s Q&A on the investigational vaccine candidate M72/AS01E
• Final Analysis of a Trial of M72/AS01E Vaccine to Prevent Tuberculosis, published in the New England Journal of Medicine
• TAG’s 2019 TB Vaccine Pipeline Report

We look forward to the conversation on February 6th!